Insider Transactions and Holdings
-
Entity Type
-
Individual
-
Role
-
Director
-
Stock Symbol
-
TRML on Nasdaq
There are no Buy or Sell transactions made by Mark Mcdade since 4/23/2024
| Security |
Num Shares |
Value |
Price $ |
Transaction Date |
Ownership |
Underlying Class |
Underlying Amount |
| Common Stock |
448K |
$14.6M |
$32.50 |
Jan 29, 2024 |
By Qiming U.S. Healthcare Fund III,L.P. |
|
|
| Common Stock |
183K |
$5.95M |
$32.50 |
Jan 29, 2024 |
By Qiming U.S. Healthcare Fund I,L.P. |
|
|
| Common Stock |
110K |
$3.58M |
$32.50 |
Jan 29, 2024 |
By Qiming U.S. Healthcare Fund II,L.P. |
|
|
| Common Stock |
518 |
$16.8K |
$32.50 |
Jan 29, 2024 |
Direct |
|
|
| Stock Option (Right to Buy) |
10K |
|
|
Jun 5, 2024 |
Direct |
Common Stock |
|
Transactions reported by Mark Mcdade for Tourmaline Bio, Inc.
| Sym |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares After |
Date |
Ownership |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.